Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Cleveland, OH
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer
Status: Enrolling
Updated:  4/25/2017
mi
from
Caen Cedex,
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer
Status: Enrolling
Updated: 4/25/2017
mi
from
Caen Cedex,
Click here to add this to my saved trials
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/4/2017
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/4/2017
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Click here to add this to my saved trials
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/4/2017
Texas Oncology PA Texas Cancer Center
mi
from
Abilene, TX
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/4/2017
Texas Oncology PA Texas Cancer Center
mi
from
Abilene, TX
Click here to add this to my saved trials
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/4/2017
Cancer Care Northwest
mi
from
Spokane Valley, WA
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/4/2017
Cancer Care Northwest
mi
from
Spokane Valley, WA
Click here to add this to my saved trials
Magnetic Resonance Imaging (MRI) in Motion
Magnetic Resonance Imaging ( MRI) for Radiation Therapy Treatment Planning Evaluation of Lung, Liver and Pancreatic Motion.
Status: Enrolling
Updated:  5/4/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Magnetic Resonance Imaging (MRI) in Motion
Magnetic Resonance Imaging ( MRI) for Radiation Therapy Treatment Planning Evaluation of Lung, Liver and Pancreatic Motion.
Status: Enrolling
Updated: 5/4/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Cognitive Behavioral Therapy (CBT)-Insomnia for Lung Cancer
Translating CBT-Insomnia for Lung Cancer Into Practice: A RCT
Status: Enrolling
Updated:  5/8/2017
SUNY-University of Buffalo
mi
from
Buffalo, NY
Cognitive Behavioral Therapy (CBT)-Insomnia for Lung Cancer
Translating CBT-Insomnia for Lung Cancer Into Practice: A RCT
Status: Enrolling
Updated: 5/8/2017
SUNY-University of Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Cognitive Behavioral Therapy (CBT)-Insomnia for Lung Cancer
Translating CBT-Insomnia for Lung Cancer Into Practice: A RCT
Status: Enrolling
Updated:  5/8/2017
Roswell Park Cancer Institute Thoracic Clinic
mi
from
Buffalo, NY
Cognitive Behavioral Therapy (CBT)-Insomnia for Lung Cancer
Translating CBT-Insomnia for Lung Cancer Into Practice: A RCT
Status: Enrolling
Updated: 5/8/2017
Roswell Park Cancer Institute Thoracic Clinic
mi
from
Buffalo, NY
Click here to add this to my saved trials
Chest Imaging, Breath, and Biomarkers in a Screening Trial
A Clinical Trial to Develop Chest Imaging, Breath, and Biomarkers in a Screening Trial
Status: Enrolling
Updated:  5/17/2017
Cleveland Clinic
mi
from
Cleveland, OH
Chest Imaging, Breath, and Biomarkers in a Screening Trial
A Clinical Trial to Develop Chest Imaging, Breath, and Biomarkers in a Screening Trial
Status: Enrolling
Updated: 5/17/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer
Status: Enrolling
Updated:  5/18/2017
New York State Psychiatric Institute
mi
from
New York, NY
A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer
Status: Enrolling
Updated: 5/18/2017
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy
Status: Enrolling
Updated:  5/23/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy
Status: Enrolling
Updated: 5/23/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  5/23/2017
Clinical Research Facility
mi
from
Sarasota, FL
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 5/23/2017
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  5/23/2017
MSD Belgium BVBA/SPRL
mi
from
Brussels,
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 5/23/2017
MSD Belgium BVBA/SPRL
mi
from
Brussels,
Click here to add this to my saved trials
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  5/23/2017
Clinical Research Facility
mi
from
Boston, MA
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 5/23/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  5/23/2017
Clinical Research Facility
mi
from
Philadelphia, PA
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 5/23/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Phoenix, AZ
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Little Rock, AR
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Bakersfield, CA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Fountain Valley, CA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Los Angeles, CA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Gainesville, FL
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Indianapolis, IN
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Lexington, KY
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
New Orleans, LA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Shreveport, LA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Scarborough, ME
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Scarborough, ME
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Springfield, MA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Springfield, MA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Duluth, MN
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Duluth, MN
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Minneapolis, MN
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Robbinsdale, MN
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Saint Louis, MO
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
St. Louis, MT
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
St. Louis, MT
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Albuquerque, NM
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Raleigh, NC
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Akron, OH
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Cincinnati, OH
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Cleveland, OH
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Toledo, OH
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Toledo, OH
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Fort Worth, TX
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
San Antonio, TX
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Green Bay, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Green Bay, WI
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
La Crosse, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
La Crosse, WI
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Madison, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Milwaukee, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Wausau, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Wausau, WI
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
Status: Enrolling
Updated:  5/31/2017
Yale University, Yale Cancer Center
mi
from
New Haven, CT
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
Status: Enrolling
Updated: 5/31/2017
Yale University, Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
Status: Enrolling
Updated:  5/31/2017
UF Health Davis Cancer Pavilion and Shands Med Plaza
mi
from
Gainesville, FL
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
Status: Enrolling
Updated: 5/31/2017
UF Health Davis Cancer Pavilion and Shands Med Plaza
mi
from
Gainesville, FL
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
Status: Enrolling
Updated:  5/31/2017
Goshen Center for Cancer Care
mi
from
Goshen, IN
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
Status: Enrolling
Updated: 5/31/2017
Goshen Center for Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
Status: Enrolling
Updated:  5/31/2017
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
Status: Enrolling
Updated: 5/31/2017
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Click here to add this to my saved trials